Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

← catalyst calendar

NCT06042920 · results posted

Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.

Phase
Phase 4
Status
Terminated
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
130actual
Sites
31
Countries
Argentina, Canada, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

Business objectives have changed

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-10-09actualWhen the study began enrolling
Primary completion2025-04-25actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-04-25actualThe whole study's end, after follow-up
First posted2023-09-21actualWhen this record first appeared on the registry
Results posted2026-04-17actualWhen the sponsor posted results to the registry
Record updated2026-04-17actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Palmoplantar Psoriasis
  • Genital Psoriasis

Interventions

  • Drug: Deucravacitinib — also filed as BMS-986165, SOTYKTU
  • Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF
Percentage of Participants Achieving Palmoplantar Psoriasis Area and Severity Index (Pp-PASI)-75 Response
measured Week 16
Percentage of Participants Achieving Static Physician's Global Assessment of Genitalia (sPGA-G) Response
measured Week 16

Posted documents

hosted by the registry — we link, never re-serve
Study Protocol and Statistical Analysis Planposted 2023-05-08 · 14.5 MB · Prot_SAP_000.pdf

Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed